ClinicalTrials.gg
RecruitingNCT05808387RE-AGESUpdated Apr 11, 2023

The Effects of Resveratrol on Sirtuins and Apoptosis Biomarkers

An interventional study of Resveratrol and Placebo in Coronary Artery Disease, Menopause and Endothelial Dysfunction, sponsored by InCor Heart Institute. Recruiting at 1 site in Brazil. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2023-04-11.

Sponsored by InCor Heart Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
55 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 152 studies in Coronary Artery Disease with a site in Brazil — 22 open to participants now, 29 under way, 4 of them phase 3. Coronary Artery Disease · Brazil.

Planned enrollment
70th of 123
80 · median 100
Started
2023
with 5 others
No phase
67 of 152
14 open now
Primary completion
2025-06
later than 5 of 28 live
Registered
128th of 152
by date
Lead sponsor
6 of 152
InCor Heart Institute

Among the 152 studies in Coronary Artery Disease with a site in Brazil, this one is the 70th largest by planned enrollment of the 123 interventional ones that give a count, is one of 6 that started in 2023, is one of 67 with no phase, reaches primary completion later than 5 of the 28 other live ones, and was the 128th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

22 of the 152 studies in Coronary Artery Disease with a site in Brazil are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 55 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 152 studies in Coronary Artery Disease with a site in Brazil, or all of them as a file.
02

Study summary

Cardiovascular diseases (CVD) and neoplasms are the main causes of death in Brazilian women. Coronary artery disease (CAD) and stroke were responsible for approximately 54% of deaths from CVD in this population. In Brazil, cancers were the second cause of death and in 2017 were responsible for 58% of deaths in women. CVD and cancer share some risk factors, and control of these factors is associated with a significant reduction in cancer incidence. These two causes of death, although apparently disparate, share similar lifestyles and health risk factors, suggesting some common pathways and basic molecular networks. In women, the presence of estrogen has protective effects against atherosclerosis and, with the decline in hormone production at menopause, the incidence and prevalence of CAD increase substantially. Although the estrogen pathway is supposed to have a central effect on this increased risk, it is still debated whether other non-estrogenic mechanisms are related, since hormone replacement alone does not reduce cardiovascular events. Sirtuins and soluble advanced glycation product receptors (sRAGE) are associated with increased vascular protection, while the role of apoptosis inhibiting proteins, a pathway linked to increased cancer incidence, is still unclear in the context of atherosclerosis. Resveratrol is a key activator of sirtuins and potentially modulates these metabolic pathways, reducing cardiovascular risk. This randomized, double-blind, parallel, placebo-controlled clinical trial will be carried out in 80 postmenopausal women with CAD to analyze the effect of treatment with resveratrol on serum concentration and gene expression of sirtuins-1 -3, in the serum sRAGE concentration and in the gene expression of apoptosis inhibitory proteins.

Read the detailed description

The objective of the study is to evaluate the influence of sirtuins stimulation by resveratrol on inhibitors of apoptosis proteins gene expression of circulation angiogenic cells of postmenopausal women with stable coronary artery disease.

A randomized, double-blind, parallel, placebo-controlled clinical trial in postmenopausal women with CAD submitted to 90 days of daily resveratrol supplementation days of daily supplementation with 1000 mg of resveratrol. Eighty women aged ≥55 years, with overweight or obesity grade 1 (BMI between 25 and 35 kg/m2) will be selected. The participants will be randomized into two groups, control (CON) and resveratrol (RES). After the screening, the participants will undergo the first clinical and laboratory evaluation including lipid and glucose metabolism, inflammatory biomarkers, serum concentrations and gene expression of sirtuin-1 and sirtuin-3 and soluble receptor of advanced glycation end products, and the gene expression of inhibitors of apoptosis proteins.

03

Conditions studied

  • Coronary Artery Disease
  • Menopause
  • Endothelial Dysfunction

Keywords

  • Coronary artery disease
  • Menopause
  • Endothelial Dysfunction
  • Sirtuin
  • Receptors of advanced glycation end products
  • Apoptosis
  • Resveratrol
  • Polyphenols
  • Cardiovascular risk
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women;
  • Diagnosed coronary artery disease;
  • Stable coronary disease;

Exclusion criteria

Exclusion Criteria:

  • hypo or hyperthyroidism,
  • rheumatic disease,
  • use of alcohol,
  • hepatic failure,
  • renal failure
  • hormone replacement therapy
  • use of insulin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Resveratrol

    Trans-resveratrol, 1000mg daily for 90 days.

    Dietary Supplement: Resveratrol

  • Placebo comparator
    Control

    Starch, 1000mg daily for 90 days.

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementResveratrol

    Trans-resveratrol, 1000 mg daily for 90 days

  • Dietary supplementPlacebo

    Starch, 1000 mg daily for 90 days

06

What researchers measure

Primary outcomes

  1. Sirtuin-1 and sirtuin-3

    Serum concentrations and gene expression

    Time frame: 90 days

  2. Inhibitors of apoptosis proteins

    Gene expression of Bcl-2, XIAP, c-IAP1, and survivin

    Time frame: 90 days

  3. sRAGE

    Serum concentrations and gene expression

    Time frame: 90 days

Secondary outcomes

  1. Inflammation

    Serum concentrations of proinflammatory cytokines

    Time frame: 90 days

  2. Cardiometabolic risk factors

    Lipid and glucometabolic profiles

    Time frame: 90 days

  3. Anthropometric measures

    BMI, skinfold thickness, and body composition

    Time frame: 90 days

07

Study locations

1 of 1 sites recruiting
  • INCOR- Heart Institute
    Sao Paulo, São Paulo 05403900, Brazil
    Recruiting
    • Antonio de Pádua Mansur, PHD · Contactapmansur@yahoo.com · 26615387
    • Antonio P Mansur, PhD · Principal investigator
    • Gustavo HF Gonçalinho · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jun 2025, 26 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 26 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Apr 11, 2023
StartActual
Mar 6, 2023
Primary completionEst.
Jun 5, 2025
CompletionEst.
Jun 5, 2026
Last update
Apr 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05808387
Lead sponsor
InCor Heart Institute
Responsible party
ANTONIO DE PADUA MANSUR (Associate Professor, InCor Heart Institute) — Principal investigator
First posted
Apr 11, 2023
Start date
Mar 6, 2023
Primary completion
Jun 5, 2025 (estimated)
Completion
Jun 5, 2026 (estimated)
Last update
Apr 11, 2023

Study contacts

Antonio P Mansur, PhD
Contact
apmansur@yahoo.com
551126615448
Antonio P Mansur, PhD
principal investigator · InCor Heart Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Resveratrol

Start the discussion